Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (882)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
Tunlametinib	DNA Damage Response Inhibitor	Solid Tumour
Molecule Tunlametinib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Tusamitamab Ravtansine	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Tusamitamab Ravtansine Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Urelumab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Urelumab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Utomilumab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Utomilumab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Vadastuximab Talirine	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vadastuximab Talirine Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vanucizumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vanucizumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vepdegestrant	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vepdegestrant Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vibostolimab	TIGIT Inhibitor	Solid Tumour
Molecule Vibostolimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
Vobramitamab Duocarmazine	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vobramitamab Duocarmazine Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Volasertib	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule Volasertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Volrustomig	Bispecific Checkpoint Antibody, PD-1 x CTLA-4	Solid Tumour
Molecule Volrustomig Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism Bispecific Checkpoint Antibody, PD-1 x CTLA-4
Vopratelimab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Vopratelimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

Tunlametinib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Tusamitamab Ravtansine Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Urelumab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Utomilumab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Vadastuximab Talirine Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vanucizumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vepdegestrant Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vibostolimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
Vobramitamab Duocarmazine Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Volasertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Volrustomig Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism Bispecific Checkpoint Antibody, PD-1 x CTLA-4
Vopratelimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

‹ 1 … 71 72 73 74 ›

Product Range

Company

Global Network

Products

All Products (882)

Tunlametinib

Tusamitamab Ravtansine

Urelumab

Utomilumab

Vadastuximab Talirine

Vanucizumab

Vepdegestrant

Vibostolimab

Vobramitamab Duocarmazine

Volasertib

Volrustomig

Vopratelimab

Tunlametinib

Tusamitamab Ravtansine

Urelumab

Utomilumab

Vadastuximab Talirine

Vanucizumab

Vepdegestrant

Vibostolimab

Vobramitamab Duocarmazine

Volasertib

Volrustomig

Vopratelimab